B4GALNT1 Antibody
-
中文名稱：B4GALNT1兔多克隆抗體
-
貨號(hào)：CSB-PA002730
-
規(guī)格：￥1090
-
圖片：
-
Western Blot analysis of Hela cells using GM2/GD2 synthase Polyclonal Antibody
-
-
其他：
產(chǎn)品詳情
-
Uniprot No.：
-
基因名：B4GALNT1
-
別名：(N acetylneuraminyl) galactosylglucosylceramide antibody; (N-acetylneuraminyl)-galactosylglucosylceramide antibody; 4 N-acetylgalactosaminyltransferase 1 antibody; 4933429D13Rik antibody; B4GALNT1 antibody; B4GN1_HUMAN antibody; Beta 1 4 N acetyl galactosaminyl transferase 1 antibody; Beta 1 4 N acetylgalactosaminyltransferase 1 antibody; Beta-1 antibody; BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE 1 antibody; BETA-1,4-N-ACETYLGALACTOSAMINYLTRANSFERASE antibody; Beta1 4GalNAc T antibody; Gal-NAc-T antibody; GALGT antibody; Galgt1 antibody; GalNAc T antibody; GalNAc-T antibody; GALNACT antibody; GD2 synthase antibody; Ggm-2 antibody; Ggm2 antibody; GM2 synthase antibody; GM2/GD2 synthase antibody; SIAT 2 antibody; SIAT2 antibody; UDP Gal:betaGlcNAc beta 1 4 N acetylgalactosaminyltransferase transferase 1 antibody; UDP N acetyl alpha D galactosamine:(N acetylneuraminyl) galactosylglucosylceramide N acetylgalactosaminyltransferase antibody
-
宿主：Rabbit
-
反應(yīng)種屬：Human,Mouse,Rat
-
免疫原：Synthesized peptide derived from the Internal region of Human GM2/GD2 synthase.
-
免疫原種屬：Homo sapiens (Human)
-
標(biāo)記方式：Non-conjugated
-
抗體亞型：IgG
-
純化方式：The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-
濃度：It differs from different batches. Please contact us to confirm it.
-
保存緩沖液：Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
-
產(chǎn)品提供形式：Liquid
-
應(yīng)用范圍：WB, ELISA
-
推薦稀釋比：
Application Recommended Dilution WB 1:500-1:2000 ELISA 1:5000 -
Protocols：
-
儲(chǔ)存條件：Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
貨期：Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
-
用途：For Research Use Only. Not for use in diagnostic or therapeutic procedures.
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情
-
功能：Involved in the biosynthesis of gangliosides GM2, GD2, GT2 and GA2 from GM3, GD3, GT3 and GA3, respectively.
-
基因功能參考文獻(xiàn)：
- Data suggest that ganglioside glycosyltransferases ST3GAL5, ST8SIA1, and B4GALNT1 are S-acylated at conserved cysteine residues located close to cytoplasmic border of their transmembrane domains; ST3Gal-II is acylated at conserved cysteine residue in N-terminal cytoplasmic tail; for B4GALNT1 and ST3Gal-II, dimer formation controls their S-acylation status. PMID: 28698248
- Novel B4GALNT1 mutations reported in two families with hereditary spastic paraplegia. PMID: 24283893
- The resukts of this study identified mutations in B4GALNT1 (GM2 synthase), encoding the enzyme that catalyzes the second step in complex ganglioside biosynthesis, as the cause of this neurodegenerative phenotype. PMID: 24103911
- Minimally disseminated disease in high risk retinoblastoma patients was detected using reverse transcriptase PCR for GD2 synthase mRNA in CSF. PMID: 23721779
- Molecular upstaging of GalNAc-T using rt-pcr was correlated with prognosis in melanoma patients PMID: 21135695
- GD2/GM2 is not a reliable biomarker in small cell lung carcinoma PMID: 19457569
- The expression of three messengers coding for SAT-1, SAT-2 and GalNAcT-1 in human samples of intestinal cancer and some cell lines (breast cancer and melanomas), was evaluated. PMID: 17119850
- Transmission disequilibrium test and case-control analysis did not detect an association of B4GALNT1 gene with T1DM. PMID: 19318031
顯示更多
收起更多
-
相關(guān)疾病：Spastic paraplegia 26, autosomal recessive (SPG26)
-
亞細(xì)胞定位：Golgi apparatus membrane; Single-pass type II membrane protein.
-
蛋白家族：Glycosyltransferase 2 family
-
數(shù)據(jù)庫鏈接：
Most popular with customers
-
-
YWHAB Recombinant Monoclonal Antibody
Applications: ELISA, WB, IHC, IF, FC
Species Reactivity: Human, Mouse, Rat
-
-
-
-
-
-
